-4.png?width=1800&height=1000&name=Home%20Testing%20Blog%20(5)-4.png)
GLP1s
Oral GLP-1 obesity treatment
Women's weight loss UK
Wegovy
Everything You Need to Know About the New Oral GLP-1 Weight Loss Pill
.png?width=48&height=48&name=Untitled%20design%20(23).png){kind=small}
TribElle Clinical Team
Reviewed by Julie Boora, Superintendent Pharmacist & Clinical Director, TribElle Health Ltd (GPhC Reg. 9012688)
MHRA approved · Now available in the UK
Wegovy is now available as a tablet — no needle required
The UK's first oral semaglutide tablet for weight management has been approved by the MHRA. Same active ingredient, no injections.
For years, weight loss medications such as Wegovy and Mounjaro have been available only as injections. Now, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first oral semaglutide tablet for weight loss and weight management — offering a needle-free alternative for eligible adults.
If you've been considering GLP-1 medication but have been put off by injections, this could be the breakthrough you've been waiting for.
What is the Wegovy tablet?
The Wegovy tablet contains semaglutide — the same active ingredient found in Wegovy injections. Semaglutide belongs to a class of medications called GLP-1 receptor agonists, which work by:
|
||
|
||
|
||
|
The tablet has been approved for adults with:
|
||
|
How effective is the Wegovy tablet?
Clinical trials have shown impressive results.
| 14–17% Average body weight loss Over 64 weeks with lifestyle changes | 20%+ Achieved by some participants Comparable to injectable Wegovy |
How do oral GLP-1 weight loss medications affect daily appetite control?
Oral GLP-1 medications such as the Wegovy tablet copy a natural gut hormone that signals fullness to the brain. Taken once daily, they reduce hunger, make you feel full sooner, slow stomach emptying and quieten food cravings (“food noise”). Most people notice appetite changes within the first few weeks, and the effect builds as the dose is increased gradually.
How the tablet controls appetite
GLP-1 (glucagon-like peptide-1) is released by your gut after you eat. The tablet imitates it in three ways:
- In the brain: it acts on the hypothalamus, your hunger and fullness control centre, so you feel satisfied sooner and stay satisfied longer.
- In the stomach: it slows how quickly food leaves the stomach, so smaller portions feel like enough. This effect is strongest early in treatment and tends to settle, while the brain-based effects continue.
- In the reward system: it dampens how appealing food cues are, such as the sight or smell of high-calorie foods. Many people describe this as less “food noise” and fewer cravings.
What a typical day may look like
| Time | What many people notice |
|---|---|
| Morning, on waking | The tablet is taken on an empty stomach with a small sip of water, followed by a 30-minute wait before food, drink or other medicines. Breakfast often comes later and may be smaller. |
| Mealtimes | Fullness arrives sooner, so a normal portion may feel like too much. |
| Between meals | Fewer cravings, snacking urges and thoughts about food. |
| Afternoon and evening | Appetite stays lower and steadier. Because the medicine builds up in the body, control is not designed to “wear off” within a day. |
| Evening | Less evening grazing and emotional eating for many people, though comfort-eating habits can persist and may need separate support. |
How it changes over time
- Weeks 1 to 4: a low starting dose, with gradual increases to limit side effects. Appetite changes are often subtle at first.
- Months 1 to 3: as the dose increases, most people notice clearer reductions in hunger and cravings.
- Long term: appetite control continues while you take it. If you stop, hunger usually returns and weight can be regained.
In the main OASIS 4 trial, people taking oral semaglutide 25 mg lost an average of 13.6% of body weight over 64 weeks, compared with 2.2% on placebo, alongside lifestyle changes.
What affects how well it controls your appetite
- Taking it correctly: swallow it whole, with a small sip of water, on an empty stomach, and wait 30 minutes before eating or drinking.
- Dose: appetite effects typically strengthen as the dose is stepped up.
- Eating pattern: smaller, protein-rich meals eaten slowly make it easier to notice fullness.
- Sleep, stress and emotional eating: these can keep appetite high even on treatment.
- Hormonal changes: appetite, sleep and mood can shift around perimenopause. If that’s you, tell your pharmacist so your whole picture is reviewed.
- Individual response: some people respond less strongly, and research shows this is a recognised pattern, not a failure.
Wegovy tablet dosage schedule
The Wegovy tablet follows a gradual dose escalation schedule to help minimise side effects. Patients should remain on each dose for at least one month before increasing.
| Treatment period | Daily dose |
|---|---|
| Month 1 | 1.5 mg daily |
| Month 2 | 4 mg daily |
| Month 3 | 9 mg daily |
| Month 4 onwards | 25 mg daily (maintenance) |
How do you take the Wegovy tablet?
Unlike most medications, oral semaglutide has specific administration instructions. Following these is essential to ensure the medication works effectively.
For best absorption — follow these steps every morning
|
||
|
||
|
||
|
Can I switch from Wegovy injections to Wegovy tablets?
Yes. According to current guidance, patients already stable on Wegovy 2.4mg weekly injections can switch directly to the oral tablet under the supervision of their prescribing clinician. However, the best transition strategy may vary depending on:
|
||
|
||
|
At TribElle, we always recommend discussing any medication switch with a qualified prescriber before making changes.
Why choose Wegovy tablets instead of injections?
Weight management isn't one-size-fits-all. Here's why many women are choosing the tablet option:
|
|
||||
|
|
Common side effects of Wegovy tablets
The side effects are similar to injectable semaglutide. Most are temporary and tend to improve as the body adjusts to treatment.
Nausea, constipation, diarrhoea, bloating and reflux are the most common, especially at the start and after dose increases. Eating too little can also cause tiredness, dizziness or low protein intake, so good nutrition and hydration still matter on treatment.
Contact your pharmacist or prescriber if you can’t keep food or fluids down, notice signs of dehydration, or your appetite is very low for a prolonged period. Seek urgent help for severe, persistent abdominal pain, which can be a sign of pancreatitis or gallbladder problems.
|
Common side effects
|
Also possible
|
Side effects are usually mild and temporary. The gradual dose escalation is specifically designed to help your body adjust and minimise discomfort.
Should you start with Wegovy tablets if you're new to GLP-1s?
If you're considering your first GLP-1 medication, the Wegovy tablet may be an excellent option if:
You dislike injections You want a clinically proven treatment You struggle with food noise You want flexibility and convenience You prefer a daily routine
The most important factor isn't whether you choose a tablet or injection. It's choosing a treatment plan that you can realistically maintain long term.
Frequently asked questions
Not yet. The tablet has received MHRA approval but is awaiting further assessment before NHS availability. Initially, it is expected to be available via private prescription through registered pharmacies like TribElle.
Both contain semaglutide, but the Wegovy tablet is specifically approved for weight management and uses a higher maintenance dose of 25mg daily. Rybelsus is approved for type 2 diabetes management at lower doses.
Clinical studies suggest weight loss outcomes are broadly comparable to injectable Wegovy when the tablet is taken as prescribed — including following the specific morning, empty-stomach instructions.
Most people begin noticing appetite changes within the first few weeks, with meaningful weight loss developing over several months. Results build over the full titration schedule — the 25mg maintenance dose is where most of the significant weight loss occurs.
Potentially yes, but switching between GLP-1 and GIP/GLP-1 medications should always be managed by a qualified clinician. The two medications work on different hormonal pathways, and your prescriber will advise on the safest transition approach for your situation.
Clinical data highlight that oral Wegovy for weight loss is highly reliable and delivers results that closely rival the original injectable option. The active ingredient, oral semaglutide, works by mimicking GLP-1, a natural hormone that regulates appetite, slows down stomach emptying, and curbs intense food cravings. For those navigating midlife weight management, consistency is key. Landmark clinical trials like the OASIS 4 study demonstrated the true weight loss effectiveness of this daily tablet:
|
||
|
The TribElle view
Weight loss isn't about chasing a number on the scales. It's about improving your health, confidence, mobility, and quality of life. The arrival of the Wegovy tablet gives women another evidence-based option to help manage weight in a way that fits their lifestyle.
Whether you're considering your first GLP-1 medication or looking to switch from injections, our clinical team can help you explore the safest and most effective option for your individual goals.
How TribElle Helps
TribElle is a UK pharmacy service led by a GPhC-registered Superintendent Pharmacist and inspected by the General Pharmaceutical Council. Our pharmacist runs a UK Wegovy tablets support group with 500+ members, so our advice reflects what people actually experience day to day, not just trial data. We help with timing, meal patterns, side effects and what to expect, and we review how appetite is changing as your dose goes up.
Supporting your body during weight loss treatment can make all the difference. From vitamins to collagen support, we've got you covered.
Ready to support your journey? Here's what we stock at TribElle.
| GLP-1 Support Pack £25 |
| Perfectil Collagen Skin £39.99 |
| Perfectil Collagen Hair £39.99 |
© TribElle Health Ltd · GPhC Registration 9012688 · tribelle.co.uk · This content is for informational purposes only. Always consult a qualified healthcare professional.
References: OASIS 4 trial (NEJM, 2025); MHRA approval of the Wegovy pill; Wegovy pill Summary of Product Characteristics (check current SmPC); Obesity Reviews, 2026, doi:10.1111/obr.70148; Frontiers in Nutrition, 2026, doi:10.3389/fnut.2026.1870484; Cheney et al., Diabetes Metab Syndr Obes, 2025.
🌱
Explore treatments
Explore treatment types that might suit you
GLP-1 injections, expert clinical support and a plan built around your body.
See weight loss treatments →Join the conversation
You don't have to go through this alone
|
|||
|